Determination That TOPICORT (Desoximetasone) Cream and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 64807 [2014-25911]

Download as PDF Federal Register / Vol. 79, No. 211 / Friday, October 31, 2014 / Notices Dated: October 27, 2014. Leslie Kux, Assistant Commissioner for Policy. FOR FURTHER INFORMATION CONTACT: [FR Doc. 2014–25910 Filed 10–30–14; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2014–N–1577] Determination That TOPICORT (Desoximetasone) Cream and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. SUMMARY: Amy Hopkins, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6223, Silver Spring, MD 20993–0002, 301– 796–5418, Amy.Hopkins@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the ‘‘listed drug,’’ which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ‘‘Approved Drug Products With Therapeutic Equivalence Evaluations,’’ which is generally known as the ‘‘Orange Book.’’ Under FDA regulations, 64807 a drug is removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). Under § 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved, (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved, and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug. FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicant, FDA withdrew approval of NDA 020611 for DOVONEX (calcipotriene) Solution and NDA 020239 for KYTRIL (granisetron hydrochloride) in the Federal Register of July 19, 2013 (78 FR 43210)). Application No. Drug Applicant NDA 017856 .............. TOPICORT (desoximetasone) Cream; Topical 0.25% ........ NDA 020239 .............. KYTRIL (granisetron HCl) Injectable; Injection, Equivalent to (EQ) 0.1 milligram (mg) Base/milliliter (mL); EQ 1 mg Base/mL; EQ 3 mg Base/mL; EQ 4 mg Base/4 mL. DOVONEX (calcipotriene) Solution; Topical, 0.005% ......... LUMIGAN (bimatoprost) Solution/Drops; Ophthalmic, 0.03%. LYBREL (ethinyl estradiol; levonorgestrel) Tablet; Oral, 0.02 mg/0.09 mg. Ketorolac Tromethamine Injectable; Injection, 15 mg/mL; 30 mg/mL. Ketorolac Tromethamine Injectable; Injection, 30 mg/mL ... Taro Pharmaceuticals North America Inc., 5 Skyline Dr., Hawthorne, NY 10532. Hoffmann La Roche Inc., 340 Kingsland St., Nutley, NJ 07110. NDA 020611 .............. NDA 021275 .............. NDA 021864 .............. ANDA 075222 ............ asabaliauskas on DSK5VPTVN1PROD with NOTICES ANDA 075228 ............ FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products listed in this document in the ‘‘Discontinued Drug Product List’’ section of the Orange Book. The ‘‘Discontinued Drug Product List’’ identifies, among other items, drug products that have been discontinued VerDate Sep<11>2014 18:51 Oct 30, 2014 Jkt 235001 Leo Pharma Inc., 1 Sylvan Way, Parsippany, NJ 07054. Allergan Inc., 2525 Dupont Dr., Irvine, CA 92623. Wyeth Pharmaceuticals Inc., P.O. Box 8299, Philadelphia, PA 19101. Bedford Laboratories Inc., 300 Northfield Rd., Bedford, OH 44146. Do. from marketing for reasons other than safety or effectiveness. Approved ANDAs that refer to the NDAs and ANDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet PO 00000 Frm 00067 Fmt 4703 Sfmt 9990 current standards, the Agency will advise ANDA applicants to submit such labeling. Dated: October 27, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–25911 Filed 10–30–14; 8:45 am] BILLING CODE 4164–01–P E:\FR\FM\31OCN1.SGM 31OCN1

Agencies

[Federal Register Volume 79, Number 211 (Friday, October 31, 2014)]
[Notices]
[Page 64807]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25911]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-1577]


Determination That TOPICORT (Desoximetasone) Cream and Other Drug 
Products Were Not Withdrawn From Sale for Reasons of Safety or 
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined that the 
drug products listed in this document were not withdrawn from sale for 
reasons of safety or effectiveness. This determination means that FDA 
will not begin procedures to withdraw approval of abbreviated new drug 
applications (ANDAs) that refer to these drug products, and it will 
allow FDA to continue to approve ANDAs that refer to the products as 
long as they meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Amy Hopkins, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6223, Silver Spring, MD 20993-0002, 301-
796-5418, Amy.Hopkins@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) 
(the 1984 amendments), which authorized the approval of duplicate 
versions of drug products approved under an ANDA procedure. ANDA 
applicants must, with certain exceptions, show that the drug for which 
they are seeking approval contains the same active ingredient in the 
same strength and dosage form as the ``listed drug,'' which is a 
version of the drug that was previously approved. ANDA applicants do 
not have to repeat the extensive clinical testing otherwise necessary 
to gain approval of a new drug application (NDA).
    The 1984 amendments include what is now section 505(j)(7) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which 
requires FDA to publish a list of all approved drugs. FDA publishes 
this list as part of the ``Approved Drug Products With Therapeutic 
Equivalence Evaluations,'' which is generally known as the ``Orange 
Book.'' Under FDA regulations, a drug is removed from the list if the 
Agency withdraws or suspends approval of the drug's NDA or ANDA for 
reasons of safety or effectiveness or if FDA determines that the listed 
drug was withdrawn from sale for reasons of safety or effectiveness (21 
CFR 314.162).
    Under Sec.  314.161(a) (21 CFR 314.161(a)), the Agency must 
determine whether a listed drug was withdrawn from sale for reasons of 
safety or effectiveness: (1) Before an ANDA that refers to that listed 
drug may be approved, (2) whenever a listed drug is voluntarily 
withdrawn from sale and ANDAs that refer to the listed drug have been 
approved, and (3) when a person petitions for such a determination 
under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if 
FDA determines that a listed drug was withdrawn from sale for safety or 
effectiveness reasons, the Agency will initiate proceedings that could 
result in the withdrawal of approval of the ANDAs that refer to the 
listed drug.
    FDA has become aware that the drug products listed in the table in 
this document are no longer being marketed. (As requested by the 
applicant, FDA withdrew approval of NDA 020611 for DOVONEX 
(calcipotriene) Solution and NDA 020239 for KYTRIL (granisetron 
hydrochloride) in the Federal Register of July 19, 2013 (78 FR 43210)).

 
------------------------------------------------------------------------
        Application No.                 Drug              Applicant
------------------------------------------------------------------------
NDA 017856....................  TOPICORT             Taro
                                 (desoximetasone)     Pharmaceuticals
                                 Cream; Topical       North America
                                 0.25%.               Inc., 5 Skyline
                                                      Dr., Hawthorne, NY
                                                      10532.
NDA 020239....................  KYTRIL (granisetron  Hoffmann La Roche
                                 HCl) Injectable;     Inc., 340
                                 Injection,           Kingsland St.,
                                 Equivalent to (EQ)   Nutley, NJ 07110.
                                 0.1 milligram (mg)
                                 Base/milliliter
                                 (mL); EQ 1 mg Base/
                                 mL; EQ 3 mg Base/
                                 mL; EQ 4 mg Base/4
                                 mL.
NDA 020611....................  DOVONEX              Leo Pharma Inc., 1
                                 (calcipotriene)      Sylvan Way,
                                 Solution; Topical,   Parsippany, NJ
                                 0.005%.              07054.
NDA 021275....................  LUMIGAN              Allergan Inc., 2525
                                 (bimatoprost)        Dupont Dr.,
                                 Solution/Drops;      Irvine, CA 92623.
                                 Ophthalmic, 0.03%.
NDA 021864....................  LYBREL (ethinyl      Wyeth
                                 estradiol;           Pharmaceuticals
                                 levonorgestrel)      Inc., P.O. Box
                                 Tablet; Oral, 0.02   8299,
                                 mg/0.09 mg.          Philadelphia, PA
                                                      19101.
ANDA 075222...................  Ketorolac            Bedford
                                 Tromethamine         Laboratories Inc.,
                                 Injectable;          300 Northfield
                                 Injection, 15 mg/    Rd., Bedford, OH
                                 mL; 30 mg/mL.        44146.
ANDA 075228...................  Ketorolac            Do.
                                 Tromethamine
                                 Injectable;
                                 Injection, 30 mg/
                                 mL.
------------------------------------------------------------------------

    FDA has reviewed its records and, under Sec.  314.161, has 
determined that the drug products listed in this document were not 
withdrawn from sale for reasons of safety or effectiveness. 
Accordingly, the Agency will continue to list the drug products listed 
in this document in the ``Discontinued Drug Product List'' section of 
the Orange Book. The ``Discontinued Drug Product List'' identifies, 
among other items, drug products that have been discontinued from 
marketing for reasons other than safety or effectiveness.
    Approved ANDAs that refer to the NDAs and ANDAs listed in this 
document are unaffected by the discontinued marketing of the products 
subject to those NDAs and ANDAs. Additional ANDAs that refer to these 
products may also be approved by the Agency if they comply with 
relevant legal and regulatory requirements. If FDA determines that 
labeling for these drug products should be revised to meet current 
standards, the Agency will advise ANDA applicants to submit such 
labeling.

    Dated: October 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-25911 Filed 10-30-14; 8:45 am]
BILLING CODE 4164-01-P